|
HVEM: A novel cosignaling molecule of major interest in melanoma. |
| |
|
No Relationships to Disclose |
| |
|
Patents, Royalties, Other Intellectual Property - Inserm transfert |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Speakers' Bureau - Bristol-Myers Squibb; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Bristol-Myers Squibb |
| |
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck; Novartis; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Roche |
Patents, Royalties, Other Intellectual Property - inserm transfert |
| |
|
Stock and Other Ownership Interests - ImageIQ |
Research Funding - GlaxoSmithKline; Innate Pharma |
Patents, Royalties, Other Intellectual Property - inserm transfert |